Drug
Apl 2
Apl 2: highest development phase Phase 3, developed by Apellis Pharmaceuticals. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Apellis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| APL-2, Pegcetacoplan NCT07214740 | Phase 3 | Geographic Atrophy Secondary to Age-related Macular Degeneration |
| APL-2 NCT03525600 | Phase 3 | Geographic Atrophy |
| APL-2 NCT03525613 | Phase 3 | Geographic Atrophy |
| APL-2 NCT04085601 | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| APL-2 NCT03226678 | Phase 2 | Warm Autoimmune Hemolytic Anemia |
| APL-2 NCT03453619 | Phase 2 | IgA Nephropathy |
Latest
No recent events.
Follow Apl 2 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.